Open AccessPhase II Study of Afatinib as Third‐Line Treatment for Patients in Korea With Stage IIIB/IV Non‐Small Cell Lung Cancer Harboring Wild‐Type EGFR
Author(s) -
Ahn MyungJu,
Kim SangWe,
Cho ByoungChul,
Ahn Jin Seok,
Lee Dae Ho,
Sun JongMu,
Massey Dan,
Kim Miyoung,
Shi Yang,
Park Keunchil
Publication year - 2015
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0419erratum
Subject(s) - medicine , afatinib , oncology , lung cancer , stage (stratigraphy) , cancer , cancer research , erlotinib , epidermal growth factor receptor , paleontology , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom